{"id":90316,"date":"2025-02-12T06:51:07","date_gmt":"2025-02-12T06:51:07","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/crossject-announces-the-reappointment-of-patrick-alexandre-and-isabelle-liebschutz-as-members-of-new-streamlined-executive-board\/"},"modified":"2025-02-12T06:51:07","modified_gmt":"2025-02-12T06:51:07","slug":"crossject-announces-the-reappointment-of-patrick-alexandre-and-isabelle-liebschutz-as-members-of-new-streamlined-executive-board","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/crossject-announces-the-reappointment-of-patrick-alexandre-and-isabelle-liebschutz-as-members-of-new-streamlined-executive-board\/","title":{"rendered":"Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board"},"content":{"rendered":"
\n

Dijon, FRANCE, February 12, 2025 \u2013 0730 (CET) \u2013 Crossject (ISIN: FR0011716265; Euronext Growth : ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free ZENEO\u00ae auto-injector to deliver life-saving medicines in emergency situations,\u00a0<\/strong>today announces that, as of February 17, its Executive Board will be made up of Patrick Alexandre, Chairman, and Isabelle Liebschutz, Quality and Regulatory Affairs Director and the Company\u2019s qualified person. Their terms of office were renewed by the Supervisory Board at its meeting on 11 February, for a period of 4 years. Olivier Gir\u00e9’s membership of the Executive Board was not renewed in view of his upcoming departure from Crossject, and will expire on February 17, 2025.<\/p>\n

The new Executive Board, appointed unanimously by the Supervisory Board, has been purposely streamlined and will focus on the final stages of ZEPIZURE\u00ae’s registration with the FDA, a key step in Crossject’s transformation towards direct marketing in the United States.<\/p>\n

Patrick Alexandre, Chairman of the Management Board, and Philippe Monnot, Chairman of the Supervisory Board, commented: \u201cOn behalf of the entire team and the Supervisory Board, we would like to warmly thank Olivier Gir\u00e9 for his major contributions to the quality of the relationships established with numerous international partners, and through all the operational stages that have enabled Crossject to validate its ZENEO\u00ae platform.\u201d<\/p>\n

Olivier Gir\u00e9 added: \u201cI would like to thank the entire Crossject team for the intense years we have together successfully dedicated to the emergence of a unique technology capable of revolutionizing the clinical value of injectables in numerous indications. I wish the team every success in the launch of ZEPIZURE\u00ae and of the rest of its current portfolio of product candidates, as well as in future initiatives exploiting the ZENEO\u00ae technology.\u201d<\/p>\n

In addition to its two members, who were part of Crossject’s founding team, the Executive Board will be able to rely on experienced executive to drive the company\u2019s growth over the next 18 months:<\/p>\n